Aberdeen Group plc lifted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 329.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 620,546 shares of the medical equipment provider's stock after acquiring an additional 475,905 shares during the quarter. Aberdeen Group plc owned about 0.33% of Zimmer Biomet worth $50,877,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Tacita Capital Inc acquired a new stake in Zimmer Biomet during the second quarter valued at approximately $26,000. Ancora Advisors LLC bought a new stake in Zimmer Biomet during the second quarter worth approximately $29,000. Elevation Wealth Partners LLC grew its position in Zimmer Biomet by 145.9% in the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider's stock worth $33,000 after buying an additional 229 shares during the last quarter. Cassaday & Co Wealth Management LLC acquired a new position in Zimmer Biomet in the first quarter worth approximately $44,000. Finally, Parvin Asset Management LLC acquired a new position in Zimmer Biomet in the second quarter worth approximately $47,000. Institutional investors own 88.89% of the company's stock.
Insider Buying and Selling
In other news, insider Chad F. Phipps sold 3,000 shares of the company's stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the transaction, the insider owned 65,231 shares of the company's stock, valued at approximately $6,415,468.85. This represents a 4.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kevin R. Thornal sold 5,691 shares of the company's stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The disclosure for this sale is available in the SEC filing. 1.28% of the stock is owned by insiders.
Zimmer Biomet Price Performance
Shares of ZBH opened at $103.18 on Monday. The firm has a market cap of $19.53 billion, a PE ratio of 26.12, a PEG ratio of 2.42 and a beta of 0.50. The firm's 50 day moving average price is $95.76 and its 200 day moving average price is $92.57. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.79 and a current ratio of 1.46. Zimmer Biomet Holdings, Inc. has a twelve month low of $79.12 and a twelve month high of $112.54.
Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a net margin of 8.95% and a return on equity of 13.02%. The business had revenue of $2.06 billion during the quarter, compared to analyst estimates of $2.04 billion. During the same quarter in the previous year, the business earned $1.90 EPS. Zimmer Biomet's quarterly revenue was up 3.1% compared to the same quarter last year. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.56 EPS for the current fiscal year.
Zimmer Biomet Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th were given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Wednesday, September 30th. Zimmer Biomet's payout ratio is currently 24.30%.
Analyst Ratings Changes
Several research firms have issued reports on ZBH. Canaccord Genuity Group increased their price objective on Zimmer Biomet from $83.00 to $100.00 and gave the company a "hold" rating in a research report on Monday, August 10th. Weiss Ratings raised Zimmer Biomet from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, September 14th. BMO Capital Markets restated a "market perform" rating on shares of Zimmer Biomet in a report on Monday, September 28th. Jefferies Financial Group restated a "hold" rating and issued a $120.00 target price on shares of Zimmer Biomet in a report on Wednesday, November 4th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a research report on Wednesday, August 5th. Seven equities research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Zimmer Biomet has an average rating of "Hold" and an average price target of $112.74.
Check Out Our Latest Research Report on Zimmer Biomet
Zimmer Biomet Company Profile
(
Free Report)
Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.
Read More
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zimmer Biomet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.
While Zimmer Biomet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.